Scott Harris
Chief Development Officer

Mr. Harris has more than 25 years of broad cross-functional experience across a range of therapeutics areas and modalities, including directing all aspects of drug development from pre-clinical to post-marketing activities. Most recently, Mr. Harris was chief operating officer of Cleave Therapeutics, a clinical stage hematology oncology company, where he oversaw all research and development activities including the clinical advancement of its investigational therapy for the treatment of acute myeloid leukemia. His biopharmaceutical career has included positions of increasing responsibility at companies such as BridgeBio, Corthera, Inc., BioMarin Pharmaceutical, Angstrom Pharmaceutical, Attenuon, LLC and Adynxx, Inc. Mr. Harris started his career as a bench scientist at Biosite Inc. He earned an M.S. in Regulatory Affairs from San Diego State University (SDSU) and a B.S. in Biochemistry and Cell Biology from University of California San Diego (UCSD). He also holds an academic appointment at SDSU where he teaches undergraduate and graduate courses in healthcare product regulation.